Evidence map›Paper›PMID 39669477›Full record

ArticleBleeding, thrombosis and vascular biology2024

Venous thromboembolism and mortality in patients with hematological malignancies.

Kristen M Sanfilippo, Tzu-Fei Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bleeding, thrombosis and vascular biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Kristen M SanfilippoDepartment of Medicine, Washington University School of Medicine, Saint Louis, MO, United States.
Tzu-Fei WangDepartment of Medicine, University of Ottawa at The Ottawa Hospital and Ottawa Hospital Research Institute, Ottawa, ON, Canada.

Funding

Prediction of Anticoagulant-Related Bleeding Risk in Patients with CancerR01HL166386 · NHLBI · WASHINGTON UNIVERSITY · PI Kristen Marie Sanfilippo · 2023 to 2026
$1.6M
Prediction and Prevention of Venous Thromboembolism in Multiple MyelomaK01HL136893 · NHLBI · WASHINGTON UNIVERSITY · PI SANFILIPPO, KRISTEN MARIE · 2017 to 2019
$484k
NHLBI NIH HHS K01 HL136893NHLBI NIH HHS L30 HL129436NHLBI NIH HHS R01 HL166386
6 · The paper itself

Abstract

Mortality and venous thromboembolism (VTE) are major risks for patients with hematological malignancies. However, they are commonly underrepresented in major clinical trials of VTE. Treatment decisions are further complicated by the unique characteristics they frequently exhibit, such as thrombocytopenia. In addition to discussing treatment challenges, knowledge gaps, and future directions, our goal in this narrative review is to provide an overview of the epidemiology and risk factors of mortality in patients with hematological malignancies and VTE.

Indexed as

cancerhematological malignanciesmortalitythrombosisvenous thromboembolism

Identifiers

PMID39669477
PMCPMC11636961

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.